RxDoctor Payments Data

John McPhail, OD

Optometrist · Boiling Springs, SCNPI 1568566719

Payments from drug & device makers

$4,035in general payments, 2019–2025

Across 141 payments — averaging $28.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$1K
  • Sight Sciences, Inc.$556
  • Biotissue Holdings Inc.$356
  • AbbVie$321
  • Alcon$291
  • Mallinckrodt Hospital Products Inc.$263
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,82195%
  • Education$1002%
  • Entertainment$1143%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,035 in reported general payments places this provider in the 85th percentile of 653 optometrist providers in South Carolina.

See all optometrist providers in South Carolina

Medicare billing

Part B allowed, 2024
$247,623
Medicare patients
1,594
Services billed
2,603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost232$93,091
RestasisCyclosporine37$53,137
CequaCyclosporine50$42,006
XiidraLifitegrast20$38,948
RocklatanNetarsudil Mesylat/Latanoprost58$24,421
Cyclosporine47$21,478
TyrvayaVarenicline Tartrate31$20,082
Alphagan PBrimonidine Tartrate20$9,113
MieboPerfluorohexyloctane/Pf12$8,774
Restasis MultidoseCyclosporine14$8,575
Travoprost49$7,103
VyzultaLatanoprostene Bunod21$6,772
Latanoprost677$5,742
CombiganBrimonidine Tartrate/Timolol17$4,954
Brimonidine Tartrate138$4,511

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Restasis Multidose, Combigan$321$168,871320 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$81$54,49553 claims
Sun Pharmaceutical Industries Inc.Cequa$1,062$42,00650 claims
Oyster Point Pharma, Inc.Tyrvaya$63$20,08231 claims
AlconSimbrinza$291$3,00115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 653 optometrist providers in South Carolina.

Other optometrist in Boiling Springs

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →